Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07860957). This is a study registration, not published results. Lead sponsor: Istanbul University - Cerrahpasa. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 37 participants (ACTUAL). Conditions: Bipolar Disorder (BPD). Interventions: DEVICE: Bright Light Therapy; DEVICE: Placebo Light Therapy. Primary outcome measures: Remission Rate Based on the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version at Week 4 , At the end of week 4. Brief summary: This randomized, double-blind, placebo-controlled study evaluated the efficacy of bright light therapy as an add-on treatment for adults with bipolar I or bipolar II disorder experiencing a mild-to-moderate depressive episode. The study examined whether bright light therapy improves depressive symptoms and also evaluated its effects on clinical status, psychosocial functioning, sleep quality, circadian characteristics, and treatment-emergent adverse effects. Participants continued their existing mood stabilizer and/or atypical antipsychotic treatment at unchanged doses and were randomly assigned to receive either active bright light therapy (10,000 lux) or placebo light therapy (1,500 lux). Both groups used the same light therapy device at home for 30 minutes daily between 12:00 PM and 2:00 PM for four weeks. Clinical assessments were conducted before treatment and weekly throughout the four-week treatment period. The primary outcome was remission at the end of week 4, defined as a the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version total score below 9.